$-0.39 EPS Expected for Corium International, Inc. (CORI)

July 11, 2018 - By Eula Gilbert

Investors sentiment decreased to 1.32 in 2018 Q1. Its down 0.47, from 1.79 in 2017Q4. It dropped, as 7 investors sold Corium International, Inc. shares while 18 reduced holdings. 14 funds opened positions while 19 raised stakes. 32.85 million shares or 6.87% more from 30.74 million shares in 2017Q4 were reported.
Credit Suisse Ag accumulated 25,800 shares or 0% of the stock. Needham Inv Management Limited Liability stated it has 0.73% of its portfolio in Corium International, Inc. (NASDAQ:CORI). Bluecrest Capital Mngmt Limited reported 40,505 shares. Awm Invest Com holds 5.02% or 2.27 million shares. Victory Cap Management has 0% invested in Corium International, Inc. (NASDAQ:CORI). Ameritas Inv Partners holds 1,747 shares. State Of Wisconsin Investment Board reported 0% stake. Barclays Public Ltd Com stated it has 6,848 shares or 0% of all its holdings. Jpmorgan Chase & reported 96,935 shares stake. Broadfin Capital Ltd Liability holds 5.58% of its portfolio in Corium International, Inc. (NASDAQ:CORI) for 3.12 million shares. Moreover, Wells Fargo & Mn has 0% invested in Corium International, Inc. (NASDAQ:CORI) for 43,174 shares. Emory University accumulated 210,559 shares. Opaleye Management Inc reported 3.49% of its portfolio in Corium International, Inc. (NASDAQ:CORI). Franklin Res reported 2.06M shares. Iguana Mgmt accumulated 110,000 shares or 0.83% of the stock.

Analysts expect Corium International, Inc. (NASDAQ:CORI) to report $-0.39 EPS on August, 2.They anticipate $0.04 EPS change or 9.30 % from last quarter’s $-0.43 EPS. After having $-0.50 EPS previously, Corium International, Inc.’s analysts see -22.00 % EPS growth. The stock increased 3.12% or $0.24 during the last trading session, reaching $7.94. About 186,325 shares traded. Corium International, Inc. (NASDAQ:CORI) has risen 23.07% since July 12, 2017 and is uptrending. It has outperformed by 10.50% the S&P500.

Corium International, Inc. (NASDAQ:CORI) Ratings Coverage

Among 2 analysts covering Corium (NASDAQ:CORI), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Corium had 7 analyst reports since February 9, 2018 according to SRatingsIntel. The rating was maintained by H.C. Wainwright with “Buy” on Friday, February 9. The stock of Corium International, Inc. (NASDAQ:CORI) has “Buy” rating given on Tuesday, May 15 by H.C. Wainwright. The stock of Corium International, Inc. (NASDAQ:CORI) earned “Buy” rating by Cantor Fitzgerald on Friday, February 9. The company was maintained on Monday, May 14 by Cantor Fitzgerald. The stock has “Buy” rating by Cantor Fitzgerald on Thursday, March 8. The stock of Corium International, Inc. (NASDAQ:CORI) earned “Buy” rating by H.C. Wainwright on Friday, June 15. The rating was maintained by Cantor Fitzgerald with “Buy” on Tuesday, March 27.

Corium International, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. The company has market cap of $287.77 million. It offers Clonidine Transdermal Delivery System , a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening. It currently has negative earnings. The company??s products under pipeline comprise Twirla, a combination hormonal contraceptive patch, which has completed Phase III clinical trials to deliver ethinyl estradiol and levonorgestrel hormones; MicroCor hPTH(1-34), a transdermal system that has completed Phase 1 and Phase II a clinical trials for the treatment of severe osteoporosis; and Donepezil and Memantine transdermal systems, which completed Phase I clinical trials for the treatment of Alzheimer's disease.

More important recent Corium International, Inc. (NASDAQ:CORI) news were published by: Seekingalpha.com which released: “An Update On Corium International” on June 15, 2018, also Nasdaq.com published article titled: “Corium Announces Issuance of Additional US Patent Covering Corplexâ„¢ Donepezil Transdermal System for …”, Investingnews.com published: “Corium Announces Issuance of Key US Patent Covering Corplex Donepezil Transdermal System for Alzheimer’s Disease” on June 13, 2018. More interesting news about Corium International, Inc. (NASDAQ:CORI) was released by: Globenewswire.com and their article: “Corium Announces Issuance of Key US Patent Covering Corplexâ„¢ Donepezil Transdermal System for Alzheimer’s …” with publication date: June 13, 2018.

Corium International, Inc. (NASDAQ:CORI) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.